<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04692831</url>
  </required_header>
  <id_info>
    <org_study_id>20-275</org_study_id>
    <nct_id>NCT04692831</nct_id>
  </id_info>
  <brief_title>Testing a New Imaging Agent to Identify Cancer</brief_title>
  <official_title>Imaging of HER2-positive Cancer With Site-Specifically Labeled 89Zr-ss-Pertuzumab</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to see whether 89Zr-ss-pertuzumab is safe in people with HER2+&#xD;
      cancer. The study will also test whether the PET/CT pictures taken using 89Zr-ss-pertuzumab&#xD;
      are better than those taken using 89Zr-pertuzumab, another imaging agent that targets the&#xD;
      HER2 protein.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 30, 2020</start_date>
  <completion_date type="Anticipated">November 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate clinical safety of 89Zr-ss-pertuzumab</measure>
    <time_frame>Up to 20 months</time_frame>
    <description>CTCAE Version 5 will be utilized for toxicity evaluation</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>HER-2 Positive Malignant Carcinoma of Breast</condition>
  <condition>HER-2 Protein Overexpression</condition>
  <condition>HER2-positive Metastatic Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in Arm A will receive 89Zr-ss-pertuzumab first, followed by 89Zr-pertuzumab. 89Zr-pertuzumab will be administered followed by 1 PET/CT scan 5-8 days post administration. For standard first in-human dosimetry, the first 6-8 patients who receive 89Zr-ss-pertuzumab will be followed by PET/CT imaging at 3 timepoints: 24 hours post administration (scan 1), 3-4 days post administration (scan 2) and 5-8 days post administration (scan 3). Once the optimal imaging timepoint for 89Zr-ss-pertuzumab is determined from these 6-8 patients, the remaining 12-14 participants will be scanned only at this optimal imaging timepoint</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in Arm B will receive 89Zr-pertuzumab first, followed by 89Zr-ss-pertuzumab. 89Zr-pertuzumab will be administered followed by 1 PET/CT scan 5-8 days post administration. For standard first in-human dosimetry, the first 6-8 patients who receive 89Zr-ss-pertuzumab will be followed by PET/CT imaging at 3 timepoints: 24 hours post administration (scan 1), 3-4 days post administration (scan 2) and 5-8 days post administration (scan 3). Once the optimal imaging timepoint for 89Zr-ss-pertuzumab is determined from these 6-8 patients, the remaining 12-14 participants will be scanned only at this optimal imaging timepoint</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>89Zr-ss-pertuzumab PET/CT</intervention_name>
    <description>Patients in Arm A will receive 89Zr-ss-pertuzumab first, followed by 89Zr-pertuzumab. Patients in Arm B will receive 89Zr-pertuzumab first, followed by 89Zr-ss-pertuzumab.</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>89Zr-pertuzumab PET/CT</intervention_name>
    <description>Patients in Arm A will receive 89Zr-ss-pertuzumab first, followed by 89Zr-pertuzumab. Patients in Arm B will receive 89Zr-pertuzumab first, followed by 89Zr-ss-pertuzumab.</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Static PET/CT scans</intervention_name>
    <description>89Zr-pertuzumab will be administered followed by 1 PET/CT scan 5-8 days post administration. For standard first in-human dosimetry, the first 6-8 patients who receive 89Zr-ss-pertuzumab will be followed by PET/CT imaging at 3 timepoints: 24 hours post administration (scan 1), 3-4 days post administration (scan 2) and 5-8 days post administration (scan 3). Once the optimal imaging timepoint for 89Zr-ss-pertuzumab is determined from these 6-8 patients, the remaining 12-14 participants will be scanned only at this optimal imaging timepoint.</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Biopsy proven HER2-positive primary malignancy or metastatic disease&#xD;
&#xD;
        Note: HER2 positivity is defined according to American Society of Clinical Oncology&#xD;
        guidelines, including 3+ HER2 IHC or 2+ HER2 IHC with HER2 amplification on fluorescence in&#xD;
        situ hybridization (FISH) of 2.0 or more.&#xD;
&#xD;
          -  Biopsy proven metastatic disease&#xD;
&#xD;
          -  At least five malignant lesions on CT, MR, or FDG PET/CT within 60 days of protocol&#xD;
             enrollment&#xD;
&#xD;
          -  Age 18 years or greater&#xD;
&#xD;
          -  ECOG performance of 0-2&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Creatinine &gt; 2 times normal limit (obtained with 8 weeks of enrollment)&#xD;
&#xD;
          -  AST/ALT &gt; 2 times normal limit (obtained with 8 weeks of enrollment)&#xD;
&#xD;
          -  Life expectancy &lt; 3 months&#xD;
&#xD;
          -  Pregnancy or lactation&#xD;
&#xD;
          -  Patients who cannot undergo PET/CT due to weight limits (over 450 pounds)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Randy Yeh, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Randy Yeh, MD</last_name>
    <phone>212-639-3776</phone>
    <email>yehr@mskcc.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jason Lewis, PhD</last_name>
    <phone>646-888-3038</phone>
    <email>lewisj2@mskcc.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>PATTY AND GEORGE HOAG CANCER CENTER (Data or Specimen Analysis Only)</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92663</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gary Ulaner, MD, PhD</last_name>
      <phone>949-722-6237</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center (All Protocol Activities)</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Randy Yeh, MD</last_name>
      <phone>212-639-3776</phone>
    </contact>
    <contact_backup>
      <last_name>E.</last_name>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mskcc.org</url>
    <description>Memorial Sloan Kettering Cancer Center</description>
  </link>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>December 30, 2020</study_first_submitted>
  <study_first_submitted_qc>December 30, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 5, 2021</study_first_posted>
  <last_update_submitted>May 4, 2021</last_update_submitted>
  <last_update_submitted_qc>May 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HER-2 Positive Malignant Carcinoma of Breast</keyword>
  <keyword>HER-2 Protein Overexpression</keyword>
  <keyword>HER2-positive Metastatic Breast Cancer</keyword>
  <keyword>3+ HER2 IHC</keyword>
  <keyword>2+ HER2 IHC</keyword>
  <keyword>20-275</keyword>
  <keyword>Memorial Sloan Kettering Cancer Center</keyword>
  <keyword>HER2-positive primary malignancy</keyword>
  <keyword>Zr-ss-Pertuzumab</keyword>
  <keyword>Zr-pertuzumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pertuzumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

